230 related articles for article (PubMed ID: 25870251)
1. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer.
Díaz-Martín J; López-García MÁ; Romero-Pérez L; Atienza-Amores MR; Pecero ML; Castilla MÁ; Biscuola M; Santón A; Palacios J
Endocr Relat Cancer; 2015 Jun; 22(3):443-54. PubMed ID: 25870251
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer.
Gorshein E; Klein P; Boolbol SK; Shao T
Clin Breast Cancer; 2014 Oct; 14(5):309-14. PubMed ID: 24703318
[TBL] [Abstract][Full Text] [Related]
4. VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer.
Castilla MÁ; López-García MÁ; Atienza MR; Rosa-Rosa JM; Díaz-Martín J; Pecero ML; Vieites B; Romero-Pérez L; Benítez J; Calcabrini A; Palacios J
Endocr Relat Cancer; 2014 Aug; 21(4):587-99. PubMed ID: 24891455
[TBL] [Abstract][Full Text] [Related]
5. Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.
Soyama H; Nishio M; Otani J; Sakuma T; Takao S; Hara S; Masuda T; Mimori K; Toyokuni S; Lydon JP; Nakao K; Nishina H; Fukumoto T; Maehama T; Suzuki A
Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2123134119. PubMed ID: 35858357
[TBL] [Abstract][Full Text] [Related]
6. Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.
Reyes C; Jorda M; Gomez-Fernández C
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):283-6. PubMed ID: 22935826
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
[TBL] [Abstract][Full Text] [Related]
8. Bone metastatic process of breast cancer involves methylation state affecting E-cadherin expression through TAZ and WWOX nuclear effectors.
Matteucci E; Maroni P; Luzzati A; Perrucchini G; Bendinelli P; Desiderio MA
Eur J Cancer; 2013 Jan; 49(1):231-44. PubMed ID: 22717556
[TBL] [Abstract][Full Text] [Related]
9. A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer.
Romero-Pérez L; Garcia-Sanz P; Mota A; Leskelä S; Hergueta-Redondo M; Díaz-Martín J; López-García MA; Castilla MA; Martínez-Ramírez A; Soslow RA; Matias-Guiu X; Moreno-Bueno G; Palacios J
Mod Pathol; 2015 Nov; 28(11):1492-503. PubMed ID: 26381823
[TBL] [Abstract][Full Text] [Related]
10. Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers.
Rao D; Kimler BF; Nothnick WB; Davis MK; Fan F; Tawfik O
Hum Pathol; 2015 Jun; 46(6):876-83. PubMed ID: 25841305
[TBL] [Abstract][Full Text] [Related]
11. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
12. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression.
Xie D; Cui J; Xia T; Jia Z; Wang L; Wei W; Zhu A; Gao Y; Xie K; Quan M
Oncotarget; 2015 Nov; 6(34):35949-63. PubMed ID: 26416426
[TBL] [Abstract][Full Text] [Related]
13. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer.
O'Hurley G; Daly E; O'Grady A; Cummins R; Quinn C; Flanagan L; Pierce A; Fan Y; Lynn MA; Rafferty M; Fitzgerald D; Pontén F; Duffy MJ; Jirström K; Kay EW; Gallagher WM
Histopathology; 2014 Apr; 64(5):660-70. PubMed ID: 24138071
[TBL] [Abstract][Full Text] [Related]
14. [Breast cancer with triple-negative phenotype in the Russian patient population. Clinical and morphologic features].
Zhukova LG
Vopr Onkol; 2015; 61(2):189-94. PubMed ID: 26087596
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
16. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma.
Xiao H; Jiang N; Zhou B; Liu Q; Du C
Cancer Sci; 2015 Feb; 106(2):151-9. PubMed ID: 25495189
[TBL] [Abstract][Full Text] [Related]
17. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
18. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
[TBL] [Abstract][Full Text] [Related]
19. High expression of TAZ indicates a poor prognosis in retinoblastoma.
Zhang Y; Xue C; Cui H; Huang Z
Diagn Pathol; 2015 Oct; 10():187. PubMed ID: 26464030
[TBL] [Abstract][Full Text] [Related]
20. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer.
Beg S; Siraj AK; Prabhakaran S; Jehan Z; Ajarim D; Al-Dayel F; Tulbah A; Al-Kuraya KS
Breast Cancer Res Treat; 2015 Jun; 151(3):541-53. PubMed ID: 25981902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
